Form 4: Macrogenics CSO Converts RSUs, Adjusts Holdings

Macrogenics' Senior VP of Research and CSO, Ezio Bonvini, reported the conversion of restricted stock units into common stock and subsequent tax-related dispositions.

Summary

• Ezio Bonvini, Senior VP, Research & CSO of Macrogenics Inc. (MGNX), reported transactions involving company common stock.
• On February 7, 2026, Bonvini acquired 7,001 shares of common stock through the conversion of restricted stock units (RSUs) and disposed of 2,703 shares at $1.81 for tax purposes.
• This conversion stemmed from a grant of 21,000 RSUs on February 7, 2025, with the first of three equal installments vesting.
• On February 8, 2026, Bonvini acquired an additional 11,166 shares of common stock from RSU conversion and disposed of 4,311 shares at $1.81 for tax purposes.
• This second conversion was from a grant of 33,500 RSUs on February 8, 2024, with the first of three equal installments vesting.
• Following these transactions, Bonvini directly beneficially owns 135,567 shares of common stock and 11,166 restricted stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine compensation event. The vesting of restricted stock units and subsequent tax-related sales are standard for executive equity plans, indicating neither strong positive nor negative sentiment regarding the company's immediate prospects, but a net increase in direct holdings is a minor positive.

Positives

• The conversion of Restricted Stock Units (RSUs) into common stock indicates the vesting of previously granted equity compensation, which is a standard part of executive remuneration.
• The net increase in direct common stock holdings (4,298 shares on 02/07/2026 and 6,855 shares on 02/08/2026) suggests continued ownership and alignment with shareholder interests.

Negatives

• The disposition of shares to cover tax liabilities (2,703 shares and 4,311 shares) represents a reduction in direct ownership, though this is a common practice for RSU vesting.
• The sale price of $1.81 for the disposed shares might be considered low depending on the company's historical stock performance, though it reflects the market price at the time of the tax-related sale.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to equity compensation vesting, are common across the biotechnology and pharmaceutical sectors. These filings provide transparency into executive compensation structures and individual holdings, but typically do not reflect strategic shifts or operational performance.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and insider holdings, showing continued alignment through equity ownership.
• Employees: Reflects standard executive compensation practices, which can influence overall employee morale and retention strategies.

Next Steps

• Future vesting of the remaining restricted stock units from the February 7, 2025, grant (two more equal installments).
• Future vesting of the remaining restricted stock units from the February 8, 2024, grant (two more equal installments).

Key Dates

Recommendation

The filing details routine insider transactions related to the vesting of restricted stock units and subsequent tax-related sales. These are expected compensation events and do not provide new information that would significantly alter the investment thesis for Macrogenics. The net increase in direct share ownership, while small, indicates continued insider alignment. Therefore, a "hold" recommendation is appropriate as this filing does not present a catalyst for a change in investment strategy.

Keywords

Macrogenics, MGNX, Ezio Bonvini, Insider Trading, Form 4, Restricted Stock Units, RSU Conversion, Equity Compensation, Officer Transactions, Common Stock